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Topliss aromatic modification structure considers two important properties, lipophilic and electronic. This study is to 
prove lipophilic and electronic properties effect of an anticancer lead compound N-(phenylcarbamothyoil) benzamide 
using in silico and in vitro method. We used in silico method that docked two derivatives (4-nitro and 4-methyl 
moieties) in the sirtuin-1 receptor (PDB ID: 4i5i) using autodock tools. They were screened for cytotoxic activity on 
T47D cells with MTT Method. The result showed that there were different activities in docking prediction and 
cytotoxic activity on T47D. 4-Nitro PCTB had more increased activity than 4-methyl.It was implied that electronic 
activity is more affecting cytotoxic activity than lipophilic properties. 
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INTRODUCTION 
Since a long ago, modification of drug structure is one of the promising methods to find new active drug 
compounds. A lead compound must be developed first with this method1. Lead compound structure 
modification varies, but changing its physical and chemical properties by adding substituent makes it more 
active as a drug2. Every substituent has its effect on pharmacokinetics and pharmacodynamics3. 
Topliss proposed guidelines for structural modification of non-mathematical, non-statistical and non-
computerized parent compounds using the basic principles of the structural relationship approach and the 
activities of the Hansch model4. The structural modification of Topliss method includes groups that have 
certain lipophilic, electronic, and steric properties at certain positions in the lead compound structure, which 
are predicted to produce compounds with higher, equal, or lower activity than the lead compound, and lastly 
to find the most profitable synthesis pathway5. 
In this study, we had structural modification of two N-(phenylcarbamothyoil)benzamide (PCTB) 
derivatives based on their lipophilic and electronic effects. N-(phenylcarbamothyoil)benzamide is known 
as cytotoxic thiourea derivatives compound that has better activity than hydroxyurea6. Tenovin 1 is a name 
given to thiourea derivatives 1-(4 acetamidophenil)3-4-tertbuthylbenzoyl) thiourea. It has been recognized 
to possess anticancer activity through synthesis and evaluation as suggested by another research. Also, it 
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owns a reputation to elevate the levels of p53 protein in vitro (which inhibits SIRT1)7. Moreover, N –( 
allylcarbamathioyl) benzamyde is also evident to have activity as breast anticancer (T47D cells)8. 
Aromatic ring modification in Topliss method only considers two properties, lipophilic and electronic9. 
Lipophilic properties affect drug penetration through the cell membrane and increase the amount of drug 
bound into a receptor, which increases its activity. While electronic properties have a role in drug solubility 
at the distribution and interaction of drug-receptor10. 
To prove lipophilic and electronic effects of N-(phenylcarbamothyoil)benzamide on cytotoxic activity, we 
used 4-Nitro and 4-Methyl to represent each effect, respectively. Nitro has strong electronic effect (σ = 
0.78) and methyl has strong lipophilic effect (π =0.56)11. Later on, we used two different cytotoxic activity 




The chemical structures were sketched using Marvin sketch software (Version 19.17.0) and converted to 
3D Form for docking studies using Avogadro (Version 1.2.0). Merk Molecular Force Field (MMFF94), 
which optimizes the geometry’s structures, was also utilized with Avogadro principles saved in .mol2. 
 
In-silico Cytotoxic Activity  Prediction 
Molecular modeling of N-(phenylcarbamothyoil) benzamide was conducted to predict the activity. A 
molecular docking method with Histon deacetylase SIRT1 (ID= 4i5i) was performed by utilizing Autodock 
software. Retrieved from PDB bank server was the Sirtuin-1 (SIRT1) enzyme. As to provide protein 
molecule ligand, AutoDock Tool (version 1.5.6) was applied. Based on experimental conducts, grid box 
values were acquired to assign the perfect grid parameters in the ligand.  
 
Synthesis 
Synthesis had been done by reacting 0.03 mol N-phenylthiourea, 0.025 mol triethylamine, and 0.025 mol 
4-Nitro/4-Methylbenzoyl chloride solution in tetrahydrofuran, followed by refluxing and stirring the 
mixture placed in a water bath and TLC, once per hour. Just as any spot appeared, the reaction was halted. 
Afterward, THF evaporation on the rotary was continued with recrystallization. The compound structure 
identification was conducted based on infrared spectroscopy, 1H-NMR, 13C-NMR, and HRMS result.12-14 
 
Cytotoxic Activity on T47D Cell 
By employing T47D, the breast cancer cells, anticancer activity is conducted in vitro. To produce 50.000 
µg/mL concentration, the test compound (5 mg) was fused in DMSO (100ul). To derive a group of standard 
working solution, the mother liquor was steadily diluted both by adding RPMI culture medium for T47D 
cells and M199 for Vero cells15.In a 96-wells microplate, a culture of T47D cancer cell was set in the 
contour of cell suspension. It was employed with 10,000 cells / pitting in terms of density for this study. 
For media control, the plate was added with empty wells followed by CO2 5% incubator, left for 24 hours. 
After the incubation period was over, the plate was taken away. With 180 degrees of reversion, the media 
was removed. Every single well was rinsed using 100µl PBS. Afterward, the plate was rotated 180 degrees 
and PBS was discarded. Set in microplate wells were the concentration of a standard working solution 
(100µL), positive control and solvent control. Each of the concentrations was then duplicated three times. 
As for media control, it was derived from the sums containing no T47D cancer cells, incubated 24 hours 
with 5% CO2 incubator at 37°. Both the plate and the incubator were then discarded after that 24 hours. 
Added to every well was 0.5 mg/ml of MTT up to 100µL/well, incubated for three hours16. After the 
incubation and the microplate were removed, terminating the reaction was proceeded by putting 100 µL 
SDS 10% in 0.1 N HCl inside the hole. Covered with aluminum paper, the microplate was nurtured with 
5% CO2 in an incubator for 24 hours and inserted in Elisa Reader at л = 595 nm. IC50 values were obtained 
using probit analysis out of the test compound.17 
 
RESULTS AND DISCUSSION 
In-silico Cytotoxic Activity Prediction 
In silico study, the result showed that both 4-NO2-PCTB and 4-CH3-PCTB has Binding Score (BS) lower 
than hydroxyurea (HU) as reference. Hence, it was predicted that they have better activity in sirtuin-1 
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receptor.  According to Table-1, 4-NO2-PCTB (-9.69 kcal/mol) has BS lower than other derivatives, 4-CH3-
PCTB (-8.34 kcal/mol). It inferred that 4-NO2 substituent donates a strong and stable ligand-protein bond 
than 4-CH3. Nitro substituent in para position has a stronger electronic effect compared to its lipophilic 
effect (σ = 0.78), while methyl in para position had stronger lipophilic effect than its electronic effect in 
QSAR parameter (π =0.56)18. This was following previous research which states the electronic properties 
play a role in the stability of interactions between drugs and receptors.19 
 
Table-1: Binding Score and Interaction Binding of 4-CH3-PCTB, 4-NO2-PCTB, and Hydroxyurea 
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Another important result from Table-1 was the interaction of 4-NO2-PCTB and 4-CH3-PCTB with sirtuin-
1. It showed that lower BS is affected by the quantity and the quality of occurring bond20. In 4-NO2-PCTB 
strengthened with 13 bonds, there are 6 hydrogen conventional bonds (GLNA345 (two bond in receptor), 
LYSA44, SERA422, HISA363,  ASNA346), 3 pi-alkyl bonds (ILEA411, ALAA262, VALA445), 1 pi-pi 
T-shaped bond (PHE A297), 1 pi-sulfur bond (PHEA273), 1 pi-sigma bond (ILEA347), and 1 pi donor 
hydrogen bond (GLNA345). However, 4-CH3-PCTB has higher BS because it was strengthened with 8 
bonds; They are 2 hydrogen conventional bonds (GLNA345, HIS A363), 1 pi donor hydrogen bond (GLN 
A345), 1 pi sigma bond(ILE A347), 1 pi sulfur bond(PHEA273), 1 pi-pi T shaped bond (PHEA297), and 2 
pi-alkyl bonds (ILEA411 and ALA A262). Therefore, in silico study result predicted that more bonds in 
ligand-receptor interaction create a stronger bond with lower binding score21. 
 
Synthesis 
The synthesis began with R-benzoyl Chloride (R=4-CH3 and 4-NO2) combined with N-phenylthiourea – a 
yellow light crystals luster and insoluble in water - in one step, from which the 4-CH3-PCTB and 4-NO2-
PCTB compounds were derived. The structure identification of the synthesized compounds was conducted 
by IR, H NMR, C NMR and HRMS spectroscopy as mentioned in the following details: 
 
N-(Phenylcarbamothioyl)-4-methyl benzamide 
White crystal, yield 77%,  m.p. 115–116 ºC. 1H NMR (DMSO-d6, 500 MHz). δ 2.45 (s, 3H,CH3); δ 7.29 (t, 
J=7.8 Hz, 1H,Ar-H); δ 7.33 (d, J=8.1 Hz, 2H, Ar-H);  δ 7.42 (t, J=7.8 Hz, 2H, Ar-H);  δ 7.71 (d, J=7.8 Hz, 
2H, Ar-H); δ 7.79 (d, J=8.1 Hz, 2H, Ar-H); δ 9.10 (s, 1H,O=C-NH-C=S); δ 12.64 (s, 1H,S=C-NH-Ar). 13C 
NMR (DMSO-d6, 125 MHz). δ 21.8 (1C, CH3); δ 124.3 (2C, Ar);  δ 127.0 (2C, Ar); δ 127.7 (1C, Ar);  128.8 
(2C, Ar); δ 129.0 (2C, Ar);   130.0 (1C, Ar); δ 137.8 (1C, Ar);   δ 145.0 (1C, Ar);  δ 167.0 (1C, C=O); δ 
178.6  (1C, C=S). IR (KBr), ν maks(cm-1): 1672 (C=O amide) ; 1603 dan 1496 (C=C Aromatic); 3313 and 
1603 (NH stretch sec. amides); 1075 dan 807 (C=S). HRMS (m/z) C15H13N2OS: (M-H)- = 269.0757 and 
Calc. Mass = 269.0749. 
 
N-(Phenylcarbamothioyl)-4-nitro benzamide 
Yellow crystal, yield 65 %,  m.p. 129–130 ºC. 1H NMR (DMSO-d6, 500 MHz) δ 6.94 (t, J= 8.0, 1H, Ar-H); 
δ 7.12 (t, J=8.0 Hz, 2H, Ar-H); δ 7.37 (d, J=8.0 Hz, 2H, Ar-H);  δ 7.76 (d, J=8.0 Hz, 2H, Ar-H);  δ 8.35 (d, 
J=8.0 Hz, 2H, Ar-H); δ 9.56 (s, 1H, O=C-NH-C=S); δ 10.54 (s, 1H, S=C-NH-Ar). 13C NMR (DMSO-d6, 
125 MHz) δ 118.7 (2C, Ar); δ 121.1 (2C, Ar);  δ 122.4 (1C, Ar); δ 122.5 (2C, Ar); δ 124.1 (2C, Ar); δ 124.9 
(1C, Ar);  δ 129.6 (1C, Ar); δ 140.3 (1C, Ar); δ 160.3 (1C, C=O); δ 171.2 (1C, C=S). IR (KBr), ν maks(cm-
1): 1651 (C=O amide); 1635 and 1497 (C=C aromatic); 3322 and 1635 (NH stretch sec amides); 1104 and 
830 (C=S). HRMS (m/z) C14H12N3O3S: (M+H)+= 302.0536 and Calc. Mass = 302.0534. 
 
Cytotoxic Activity 
In vitro MTT Assay in T47D result showed the same activity to in silico study. IC50  4-NO2-PCTB (0.12 
mM) was lower than 4-CH3-PCTB (1.08 mM). In other words, 4-NO2-PCTB is more potent than 4-CH3-
PCTB as an anticancer agent in T47D. The effect of the electron withdrawal group is stronger than the 
electron contributor group.  
Both of 4-NO2-PCTB and 4-CH3-PCTB had better activity than hydroxyurea as reference. They also had 
cancer cell-targeted mechanisms from the cytotoxic assay in Vero cell as a normal cell. The result was both 
of them toxic in T47D cell but not in vero cell. Thus, they are worthy to develop as an anticancer agent in 
T47D cells with mechanism prediction of sirtuin-1 receptor inhibition. 
 
Table-2: RS, IC50 T47D, and Vero Cells Values of Test Compounds and Reference Compounds 
Compounds RS (Kcal/mol) IC50 T47D Cells(mM) IC50 Vero Cells(mM) 
4-CH3-PCTB -8.34 1.08 ± 0.013 53.58±0.004 
4-NO2-PCTB -9.69 0.12± 0.014 65.63±0.003 
HU -2.26 4.58± 0.019 369.88±0.015 
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To develop another derivative of N-(phenylcarbamothyoil)benzamide, structural modification in the 
aromatic compound must be considered in the selection of moiety with another electron withdrawal group 
with a higher electronic parameter σ (+) but slightly higher lipophilic parameter (π). It should still use the 
Lipinski rule because the activity is affected by the physicochemical characteristic of the moiety. 
Furthermore, in silico study in both derivatives supports invitro cytotoxic activity assay. Hence, in silico 
study can be used as activity prediction before synthesis and in vitro study. 
 
CONCLUSION 
In N-(phenylcarbamothyoil)benzamide derivatives compounds, nitro substituent has a stronger cytotoxic 
effect than methyl. It can be concluded that the N-(phenylcarbamothyoil) benzamide derivatives compound 
has a stronger electronic effect than the lipophilic effect. This can be used to develop more anticancer agent 
compounds from this lead compound. 
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